04:16 PM EST - Medicenna Therapeutics Corp. : Announced that the United States Patent and Trademark Office issued another patent related to the Company's Superkine platform. U.S. Patent 9,738,696 issued to the Board of Trustees of the Leland Stanford Junior University and licensed exclusively to Medicenna, covers the composition of engineered interleukin-4. Superkines. Medicenna Therapeutics Corp.
shares T.MDNA are trading up $0.26 at $2.41.
